Welcome to our dedicated page for Arcutis Biotherapeutics news (Ticker: ARQT), a resource for investors and traders seeking the latest updates and insights on Arcutis Biotherapeutics stock.
Arcutis Biotherapeutics, Inc. (ARQT) is a leader in developing innovative topical therapies for immune-mediated skin conditions. This page provides investors and medical professionals with essential updates on FDA approvals, clinical trial progress, and strategic initiatives shaping the future of dermatological care.
Access authoritative information about ARQT's non-steroidal treatments for conditions including atopic dermatitis and plaque psoriasis. Our curated news collection features regulatory milestones, research developments, and market analyses to help stakeholders track the company's progress in addressing unmet medical needs.
Key updates include new product launches, clinical trial results, partnership announcements, and scientific presentations. All content is verified through primary sources to ensure accuracy and compliance with financial disclosure standards.
Bookmark this page for streamlined access to Arcutis' latest advancements in immuno-dermatology. Check regularly for updates on pipeline developments and peer-reviewed research findings that demonstrate the company's commitment to transforming skin disease treatment.
Arcutis Biotherapeutics (Nasdaq: ARQT) will present new data analyses for ZORYVE® (roflumilast) at the 34th Annual EADV Congress. The presentations highlight three key findings:
1. ZORYVE foam 0.3% showed significant efficacy in treating seborrheic dermatitis across diverse skin types, with 79.5% success rate vs 58.0% for vehicle in the STRATUM trial.
2. ZORYVE cream 0.05% demonstrated improved quality of life and reduced family impact in children aged 2-5 years with atopic dermatitis in the INTEGUMENT-PED trial.
3. Both ZORYVE cream 0.3% and foam 0.3% showed effectiveness in treating plaque psoriasis with facial/genital involvement in the DERMIS-1/2 and ARRECTOR trials.
Arcutis Biotherapeutics (NASDAQ:ARQT) announced that its flagship product ZORYVE has received the prestigious 2025 Best of Beauty Breakthrough Award from Allure magazine. ZORYVE is the first FDA-approved medication for three major inflammatory skin conditions: atopic dermatitis (eczema), plaque psoriasis, and seborrheic dermatitis to win this award.
The product has emerged as the number one prescribed branded topical therapy across these three conditions combined. ZORYVE is a steroid-free, once-daily treatment available in both cream and foam formulations, featuring a unique water-based, moisturizing formula that can be used anywhere on the body and is suitable for all skin and hair types.
Arcutis Biotherapeutics (Nasdaq: ARQT), a commercial-stage biopharmaceutical company specializing in immuno-dermatology, has announced the grant of 35,500 restricted stock units to four newly hired employees. The grants were approved by the company's Compensation Committee under the 2022 Inducement Plan.
The stock units, granted on September 2, 2025, will vest over a four-year period, with 25% vesting annually, contingent on continuous employment. This announcement is made in compliance with Nasdaq Listing Rule 5635(c)(4), which governs inducement grants for new employees.
Arcutis Biotherapeutics (NASDAQ:ARQT) has submitted a supplemental New Drug Application (sNDA) to the FDA to expand the indication of ZORYVE® (roflumilast) cream 0.3% for treating plaque psoriasis in children ages 2 to 5. Currently approved for adults and children aged 6 and above, if approved, ZORYVE would become the first topical PDE4 inhibitor indicated for plaque psoriasis in children as young as 2.
The sNDA submission is supported by data from a 4-week Maximal Usage Systemic Exposure (MUSE) study in children aged 2-5 years and a long-term open-label study. The once-daily, steroid-free cream has demonstrated consistent favorable long-term safety, tolerability, and efficacy across age ranges, particularly beneficial for sensitive areas like intertriginous skin where psoriasis commonly presents in children.
Arcutis Biotherapeutics (Nasdaq: ARQT), a commercial-stage biopharmaceutical company specializing in immuno-dermatology innovations, has announced its participation in three major investor conferences in September 2025.
The company will participate in Citi's 2025 Biopharma Back to School Conference (September 3), Morgan Stanley's 23rd Annual Global Healthcare Conference (September 9), and the HC Wainwright 27th Annual Global Investment Conference (September 10). All presentations will be available via webcast in the "Events" section of Arcutis' website, with replays accessible for 180 days after each conference.
Arcutis Biotherapeutics (Nasdaq: ARQT), a commercial-stage biopharmaceutical company specializing in immuno-dermatology, has announced the grant of 21,000 restricted stock units to three new employees. The grants were approved by the company's Compensation Committee and issued under the 2022 Inducement Plan.
The stock units, granted on August 1, 2025, will vest over a four-year period, with 25% vesting annually on each anniversary of the vesting commencement date. The grants were made in accordance with Nasdaq Listing Rule 5635(c)(4) as an employment inducement.
Arcutis Biotherapeutics (Nasdaq: ARQT) reported strong Q2 2025 financial results, with net product revenue of $81.5 million, representing a 164% year-over-year increase and 28% sequential growth. The quarter was marked by significant achievements, including FDA approval of ZORYVE foam 0.3% for plaque psoriasis treatment and the initiation of the INTEGUMENT-INFANT study for ZORYVE cream in infants with atopic dermatitis.
Key financial metrics include reduced net loss of $15.9 million ($0.13 per share) compared to $52.3 million in Q2 2024, with cash reserves of $191.1 million. The company's ZORYVE portfolio showed strong performance across all formulations, with over 1 million total prescriptions dispensed to date. Additionally, Arcutis submitted an IND for ARQ-234, a novel fusion protein for atopic dermatitis treatment.
Arcutis Biotherapeutics (Nasdaq: ARQT), a commercial-stage biopharmaceutical company specializing in immuno-dermatology innovations, has scheduled its second quarter 2025 financial results announcement for August 6, 2025 after market close.
The company will host a conference call and webcast at 4:30 p.m. ET on the same day. Investors can access the live webcast and presentation materials through the "Events" section of Arcutis' website, with an archived replay available afterward on their investor website.
Arcutis Biotherapeutics (Nasdaq: ARQT), a commercial-stage biopharmaceutical company specializing in immuno-dermatology, has announced the granting of 14,000 restricted stock units to two new employees. The grants were approved by the company's Compensation Committee under the 2022 Inducement Plan, effective July 1, 2025.
The restricted stock units have a four-year vesting schedule, with 25% vesting annually, contingent on continuous employment. This grant was made in accordance with Nasdaq Listing Rule 5635(c)(4) as an employment inducement.
Arcutis Biotherapeutics (Nasdaq: ARQT) announced that its product ZORYVE® (roflumilast) cream 0.15% has received a strong recommendation in the American Academy of Dermatology's (AAD) updated guidelines for adult atopic dermatitis management. ZORYVE is the first FDA-approved branded topical PDE4 inhibitor for atopic dermatitis, plaque psoriasis, and seborrheic dermatitis.
Among newly evaluated branded topical therapies, ZORYVE stands out as the only treatment with a strong recommendation for adults with mild to moderate atopic dermatitis. The recommendation highlights the drug's efficacy in improving pruritus and disease severity, favorable tolerability, and low discontinuation rates. The treatment targets a condition affecting over 16 million adults in the United States.
FAQ
What is the current stock price of Arcutis Biotherapeutics (ARQT)?
What is the market cap of Arcutis Biotherapeutics (ARQT)?
